A multicenter study of costs of drugs in rheumatoid arthritis in China
Xiu-ru WANG,Yin SU,Yuan AN,Yun-shan ZHOU,Li-zhi WANG,Cai-hong WANG,Xiao-feng LI,Li-na CHEN,Ping ZHU,Xin LU,Guo-chun WANG,Hong-tao JIN,Rong YANG,Yong-fu WANG,Guang-tao LI,Zhuo-li ZHANG,Lin SUN,Xiang-yuan LIU,Jie-mei TAO,Feng-xiao ZHANG,Jing YANG,Zhen-bin LI,Mei-qiu WEI,Jin-ying LIN,Rong SHU,Liu-fu CUI,Dan KE,Xiao-min LIU,Cong YE,Shao-xian HU,Hao LI,Xiu-yan YANG,Bei LAI,Ming GAO,Ci-bo HUANG,Li-jun SONG,Xing-fa LI,Zhan-guo LI
DOI: https://doi.org/10.3760/cma.j.issn.1007-7480.2010.06.003
2010-01-01
Abstract:Objective To describe the distribution of medication costs of rheumatoid arthritis patients, and to analyze the factors that may affect the costs. Methods Data were obtained from a 12-month retrospective investigation of patients with rheumatoid arthritis (RA) across China. Department of Rheuma-tology of 18 hospitals were randomly selected. The data about their social conditions, clinical conditions, medications associated with RA such as disease-modifying antirheumatic drugs (DMARDs), non -steroidal anti -inflammtory drugs (NSAIDs), steroids, biologic agents were collected, and the costs of drugs were calculated. A non-parameter test and multivariate logistic regression analysis were performed. Results Six hundred and forty six patients were enrolled into the study, 435 completed data were chosen for analysis. The results demonstrated that the average costs per patient for medications in the past year was 8018 . The total medication costs were further subdivided into the following parts: DMARDs, (represented 20% of the total costs), biologic drugs (49%), NSAIDs (4%), herbal drugs (22%), steroids (1%). Data analysis showed that patients with higher education and higher incomes, with medical insurance,better health function status and outpatients paid more on DMARDs. Extra-articular manifestations increased the odds of the high-cost group (OR: 2.180, 95%CI: 1.335～3.558, P=0.002), while poor health function status increased the probability of paying high costs (OR: 1.373, 95%CI: 1.012～1.863, P=0.041). Conclusion High medication costs in RA do exist in RA patients. The costs of medication is associated with health function status and the presence of extra-articular manifestations.